---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-029710"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2026-06-23T12:30:46+00:00"
generated_at: "2026-06-23T12:35:31.463197+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics appoints Dr. Corsee Sanders to board; board expands to six

## Summary
- Dr. Corsee Sanders appointed as Class III director effective June 17, 2026, term to 2029 annual meeting.
- Board size increased from 5 to 6; Scott Leftwich removed from Audit Committee but remains on board.
- Sanders brings 30+ years pharma experience including Genentech/Roche SVP and Juno/Celgene EVP roles.
- Initial equity award for Sanders deferred pending board assessment of available shares under equity plan.

## SEC filing metadata
- accession: 0001493152-26-029710
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2026-06-23T12:30:46+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/0001493152-26-029710-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315226029710/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-029710
- JSON: https://secwatch.observer/filing/0001493152-26-029710.json
- Plain text: https://secwatch.observer/filing/0001493152-26-029710.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.